PriceTargets.com logo

Vir Biotechnology - VIR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $49.75
  • Forecasted Upside: 90.98%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$26.05 As of 05/26/2023 09:48 PM ET
▲ +0.28 (1.09%)

This chart shows the closing price for VIR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vir Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIR

Analyst Price Target is $49.75
▲ +90.98% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Vir Biotechnology in the last 3 months. The average price target is $49.75, with a high forecast of $100.00 and a low forecast of $27.00. The average price target represents a 90.98% upside from the last price of $26.05.

This chart shows the closing price for VIR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Vir Biotechnology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/5/2023SVB SecuritiesLower Target$43.00 ➝ $42.00Low
4/19/2023Needham & Company LLCReiterated RatingBuy$32.00Low
4/4/2023Morgan StanleyBoost TargetEqual Weight$25.00 ➝ $27.00Low
3/6/2023HC WainwrightLower TargetBuy$125.00 ➝ $100.00Low
3/6/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$35.00 ➝ $34.00Low
2/24/2023Needham & Company LLCReiterated RatingBuy$32.00N/A
2/21/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$41.00 ➝ $53.00Low
1/27/2023SVB LeerinkLower TargetOutperform$45.00 ➝ $43.00Low
1/27/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight$18.00 ➝ $30.00Low
11/4/2022Morgan StanleyBoost TargetUnderweight$15.00 ➝ $18.00Low
11/4/2022SVB LeerinkBoost TargetOutperform$40.00 ➝ $45.00Low
11/4/2022Needham & Company LLCLower TargetBuy$35.00 ➝ $32.00Low
9/14/2022SVB LeerinkInitiated CoverageOutperform$40.00Low
9/9/2022Morgan StanleyInitiated CoverageUnderweight$15.00Low
8/15/2022BarclaysLower Target$67.00Low
7/14/2022HC WainwrightReiterated RatingBuy$125.00Low
5/12/2022HC WainwrightLower Target$250.00 ➝ $125.00High
5/2/2022HC WainwrightReiterated RatingBuy$200.00High
3/30/2022HC WainwrightLower TargetBuy$300.00 ➝ $200.00High
3/28/2022Needham & Company LLCLower TargetBuy$80.00 ➝ $45.00High
3/3/2022Robert W. BairdUpgradeUnderperform ➝ Neutral$36.00 ➝ $28.00Low
12/21/2021HC WainwrightBoost TargetBuy$200.00 ➝ $300.00High
12/21/2021Robert W. BairdDowngradeNeutral ➝ Underperform$36.00High
12/8/2021HC WainwrightReiterated RatingBuy$199.00Low
11/30/2021HC WainwrightBoost TargetBuy$135.00 ➝ $200.00High
11/17/2021Needham & Company LLCReiterated RatingBuy$79.00High
10/25/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$29.00 ➝ $37.00Medium
9/22/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$64.00 ➝ $62.00High
8/6/2021BarclaysLower TargetOverweight$96.00 ➝ $71.00Medium
6/28/2021Needham & Company LLCReiterated RatingBuy$80.00Low
4/16/2021Needham & Company LLCReiterated RatingBuy$80.00High
3/8/2021HC WainwrightBoost TargetBuy$125.00 ➝ $135.00Low
3/8/2021Needham & Company LLCBoost TargetBuy$75.00 ➝ $80.00N/A
3/3/2021The Goldman Sachs GroupBoost TargetBuy$59.00 ➝ $61.00High
3/2/2021Needham & Company LLCBoost TargetBuy$62.00 ➝ $75.00High
2/25/2021BarclaysBoost TargetPositive ➝ Overweight$61.00 ➝ $77.00High
1/27/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$30.00High
1/20/2021HC WainwrightBoost TargetBuy$100.00 ➝ $125.00Medium
12/25/2020Robert W. BairdReiterated RatingSell$24.00N/A
12/24/2020Robert W. BairdReiterated RatingSell$24.00N/A
10/7/2020HC WainwrightBoost TargetBuy$80.00 ➝ $100.00Low
10/5/2020Bank of AmericaInitiated CoverageBuy$55.00 ➝ $55.00High
9/21/2020HC WainwrightBoost TargetBuy$75.00 ➝ $80.00High
9/14/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$48.00 ➝ $54.00Low
9/11/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$30.00 ➝ $29.00Low
8/31/2020The Goldman Sachs GroupBoost TargetNeutral$43.00 ➝ $48.00High
8/24/2020HC WainwrightReiterated RatingBuy$75.00High
8/20/2020Needham & Company LLCInitiated CoverageBuy$62.00Medium
8/12/2020BarclaysBoost TargetOverweight$44.00 ➝ $61.00Low
5/13/2020BarclaysBoost TargetOverweight$41.00 ➝ $44.00High
3/29/2020BarclaysReiterated RatingBuy$41.00High
3/27/2020Robert W. BairdBoost TargetUnderperform$17.00 ➝ $20.00Medium
3/19/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$26.00High
3/13/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$37.00High
2/27/2020Robert W. BairdDowngradeNeutral ➝ Underperform$17.00High
2/4/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $26.00Low
11/19/2019CowenInitiated CoverageBuyMedium
11/13/2019Robert W. BairdInitiated CoverageNeutralLow
11/5/2019The Goldman Sachs GroupInitiated CoverageBuy$37.00Medium
11/5/2019BarclaysInitiated CoverageOverweight$25.00Medium
11/5/2019JPMorgan Chase & Co.Initiated CoverageOverweight$25.00Medium
11/5/2019CowenInitiated CoverageOutperformMedium
(Data available from 5/29/2018 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
10/31/2022
  • 7 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/30/2022
  • 13 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 16 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/28/2023
  • 12 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
3/30/2023
  • 8 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2023
  • 14 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/29/2023

Current Sentiment

  • 14 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Vir Biotechnology logo
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $26.05
Low: $25.66
High: $26.26

50 Day Range

MA: $24.39
Low: $22.26
High: $26.73

52 Week Range

Now: $26.05
Low: $18.05
High: $31.78

Volume

618,100 shs

Average Volume

942,390 shs

Market Capitalization

$3.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Vir Biotechnology?

The following Wall Street research analysts have issued stock ratings on Vir Biotechnology in the last year: Barclays PLC, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for VIR.

What is the current price target for Vir Biotechnology?

8 Wall Street analysts have set twelve-month price targets for Vir Biotechnology in the last year. Their average twelve-month price target is $49.75, suggesting a possible upside of 91.0%. HC Wainwright has the highest price target set, predicting VIR will reach $100.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $27.00 for Vir Biotechnology in the next year.
View the latest price targets for VIR.

What is the current consensus analyst rating for Vir Biotechnology?

Vir Biotechnology currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VIR will outperform the market and that investors should add to their positions of Vir Biotechnology.
View the latest ratings for VIR.

What other companies compete with Vir Biotechnology?

Other companies that are similar to Vir Biotechnology include Ginkgo Bioworks, Abcam, Krystal Biotech, Revolution Medicines and Immunovant. Learn More about companies similar to Vir Biotechnology.

How do I contact Vir Biotechnology's investor relations team?

Vir Biotechnology's physical mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The company's listed phone number is 415-906-4324 and its investor relations email address is [email protected]. The official website for Vir Biotechnology is www.vir.bio. Learn More about contacing Vir Biotechnology investor relations.